Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedLink acquires MedAppz
The addition of MedAppz’ iSuite EHR broadens MedLink’s technology offerings, enabling the company to provide a web-based solution built on the latest Microsoft .Net 4.0 platform. MedAppz claims
The addition of MedAppz’ iSuite EHR broadens MedLink’s technology offerings, enabling the company to provide a web-based solution built on the latest Microsoft .Net 4.0 platform. MedAppz claims
Mitsui has invested $12.5m in cash in return for new convertible Preference Shares giving Mitsui 12.2% of the enlarged share capital of Hutchison MediPharma. Mitsui Global Investment Department
GLG Pharma said that the proceeds of the grant will be used to advance the development of three product candidates, GLG-202, GLG-302, GLG-401, all STAT3 inhibitors, representing a
The primary endpoint was the achievement of clinical remission, defined as a UCDAI score = 1 after eight weeks of treatment with a score of 0 for rectal
Accoding to Affymax, the decrease in revenue was the result of decreased collaboration revenue, driven primarily by lower reimbursement of clinical trial expenses, from its collaboration with Takeda
EnVivo claimed that, by acting as a co-agonist and sensitising the alpha-7 receptor, EVP-6124 makes it possible for smaller amounts of naturally occurring ACh, typically found in individuals
The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies (Ames, micronucleus, and chromosome aberration), and toxicokinetic studies. According to WuXi PharmaTech, the
Halozyme has posted a net loss of $12.4m for the third quarter 2010, or $0.13 loss per diluted share, compared to net loss of $13.91m, or $0.16 loss
The study reported on the use of non-invasive technologies for quantitative sweat function, and correlated these results with the nature and location of ectodysplasin A (EDA) gene defects
The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010. NP001 is